NEW YORK (GenomeWeb News) — Invitrogen will exclusively market pharmaceutical-grade insulin made by Indian biotech Biocon to global cell-culture customers, Invitrogen said yesterday.
 
Invitrogen said Biocon’s insulin is equivalent to others used for cell-culture bio-manufacturing and in delaying apoptosis in mammalian cell cultures.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.